Amyotrophic Lateral Sclerosis Statistics in US | ALS Facts

What Is Amyotrophic Lateral Sclerosis (ALS)?

Amyotrophic Lateral Sclerosis (ALS) — popularly known as Lou Gehrig’s disease after the celebrated New York Yankees first baseman who was diagnosed in 1939 — is a progressive, fatal neurodegenerative disease that destroys the motor neurons in the brain and spinal cord responsible for controlling voluntary muscle movement. The name itself describes the pathology: “amyotrophic” means no muscle nourishment, “lateral” refers to the areas of the spinal cord where affected nerve cells are located, and “sclerosis” describes the hardening or scarring of the region as neurons die. As upper and lower motor neurons progressively degenerate, the brain loses its ability to initiate and control muscle movement — leading to weakness, muscle atrophy, paralysis, and ultimately respiratory failure, which is the most common cause of death. Cognitive function is typically preserved in the majority of patients, meaning people with ALS remain fully aware of what is happening to their bodies throughout the disease’s progression. In approximately 30–50% of cases, some degree of cognitive impairment or behavioral changes occur, and around 5–10% develop frontotemporal dementia (FTD) — one of the most psychologically devastating aspects of a disease that already extracts an enormous emotional toll. There is currently no cure for ALS, and treatment remains focused on slowing progression and improving quality of life.

The scale of ALS in the United States is both clinically significant and directionally alarming. According to a landmark study by the CDC’s National ALS Registry, published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration in January 2025, there were an estimated 32,893 people living with ALS in the US in 2022 — a prevalence of 9.9 per 100,000 people. That number is projected to rise by more than 10% to over 36,308 cases by 2030 (a prevalence of 10.5 per 100,000), driven primarily by the aging of the US population. Among individuals 66 years and older specifically, the projected increase is a striking 25%. Approximately 5,000 new ALS diagnoses are made in the United States every year — an average of 15 new cases every single day. The disease kills roughly 7,000 Americans annually, making it the most common adult-onset motor neuron disease in the country. Historically it has been classified as a rare disease, but the CDC researchers themselves cautioned that these estimates are likely an undercount, noting that emerging therapeutics and improved healthcare may improve survivability and push actual case numbers higher than projected. The economic burden is devastating: healthcare costs for US patients rise from an average of $31,000 annually in early-stage ALS to over $120,000 in late-stage disease, among the highest cost trajectories for any neurological condition.

Interesting Facts about ALS in the US

Source: CDC National ALS Registry / Mehta et al. (January 2025, PubMed); ALS News Today (January 8, 2025); ALS News Today (November 14, 2025); PMC prevalence projection study (November 2025); ALS Association facts and statistics; Cleveland Clinic ALS page (updated 2025); Muscular Dystrophy Association; ALS NC statistics; JMCP / ALS News Today (December 2024); ALS Wikipedia (updated April 2026)

These numbers reveal a disease that, despite affecting far fewer people than cancer or heart disease, carries a uniquely concentrated burden. The $120,000+ annual late-stage healthcare cost — combined with the typically rapid disease progression — means families often face catastrophic financial strain on top of the profound emotional weight of watching a loved one lose function while remaining cognitively present. The 15 new diagnoses per day figure reflects a steady, inexorable pace: ALS does not cluster in outbreaks, does not respond to preventive vaccines, and does not have a known modifiable cause in the vast majority of cases. The geographic range of 2.6 to 7.8 per 100,000 across US states — with Vermont triple the rate of Hawaii — points to the likely influence of genetic ancestry patterns, environmental exposures, and regional demographic differences on incidence. The US Midwest’s highest ALS death rates align with some research suggesting agricultural and industrial exposures may play a role in disease risk in that region.

The 25% projected increase in cases among Americans 66 and older by 2030 is perhaps the most policy-relevant number in the entire dataset. ALS has historically been thought of as predominantly a disease of middle age, but as the Baby Boom generation moves through its 70s and 80s, the absolute number of elderly patients will rise steeply — and elderly patients with ALS face median survivals under two years, distinct comorbidity profiles, and often greater barriers to accessing the specialized multidisciplinary ALS clinic care associated with the best outcomes. The CDC researchers explicitly stated that these projections are “believed to be an underestimation” — meaning the true burden facing US healthcare in the 2030s may be significantly larger than even these concerning numbers suggest.

ALS Symptoms in the US | Clinical Signs & Progression Data

Source: Cleveland Clinic ALS page (updated 2025), ALS Wikipedia (updated April 2026), PMC — “Prognostic Factors in ALS: A Critical Review,” ALS United Chicago life expectancy guide (November 2024), ALS Association medications page

The symptom profile of ALS is one of the cruelest in all of medicine — a disease that progressively silences the body while leaving the mind intact in the majority of cases. Patients describe the experience of watching their voluntary muscle control disappear piece by piece, while their thoughts, memories, and awareness remain essentially unaffected. The average diagnostic delay of 12–18 months from first symptoms is itself a medical problem: because ALS shares early symptoms with many more common conditions (herniated discs, carpal tunnel syndrome, stroke, peripheral neuropathy), patients often spend over a year cycling through specialists before receiving a definitive diagnosis. That delay matters clinically, because the earlier medications like riluzole are started, the more survival benefit they may confer. It also matters emotionally and practically — an ALS diagnosis triggers immediate legal, financial, and care-planning decisions, and delayed diagnosis means delayed preparation.

The survival statistics by onset site illuminate one of ALS’s most clinically important variables. Bulbar-onset patients — those whose first symptoms are speech and swallowing difficulties — fare significantly worse than limb-onset patients: a median survival of 2.0 years versus 2.6 years, and a 10-year survival rate of just 3% versus 13%. Respiratory-onset patients face the bleakest trajectory of all, with a median survival of just 1.4 years and zero 10-year survivors in population studies. Understanding these distinctions matters because bulbar-onset occurs disproportionately in older women and can be initially misattributed to stroke or throat conditions, potentially compounding the diagnostic delay problem. The cognitive and behavioral changes that affect 30–50% of patients add another dimension of complexity to ALS care — they can impair the patient’s ability to participate in decision-making about their own treatment, require additional caregiver support, and significantly increase the emotional and financial burden on families.

ALS Genetics & Risk Factors in the US | Cause & Susceptibility Data

Source: ALS Association genetics page, ScienceDirect genetic architecture review (May 2025), PMC C9orf72 penetrance study (Nature Scientific Reports), Cleveland Clinic ALS page, ALS Association fALS resource booklet, BCBSM genetic testing policy (2025), Target ALS statistics page, ALS News Today facts page

The genetics of ALS is one of the most complex stories in neurodegenerative disease research, and understanding it is critical to understanding both who is at risk and why current treatments work for some patients but not others. The 10% familial / 90% sporadic split has long been the foundational epidemiological fact about ALS, but that framing is increasingly recognized as oversimplified. Many people classified as “sporadic” actually carry pathogenic gene variants — including C9orf72 expansions and SOD1 mutations — that were simply not detected before genetic testing became routine in ALS care. The 2025 ScienceDirect review confirmed that genetic variants now explain approximately 70% of familial ALS cases and 15% of sporadic ALS cases, suggesting the true proportion of genetically-driven ALS is considerably higher than the family-history data implies.

The C9orf72 discovery in 2011 was genuinely transformative for the ALS research community. The mutation — a massive expansion of a normally tiny hexanucleotide repeat sequence — turned out to be not only the most common genetic cause of ALS but also the most common genetic cause of frontotemporal dementia, linking the two diseases at the molecular level. C9orf72 accounts for 25–40% of familial ALS and roughly 7.7% of all ALS cases including sporadic, making it by far the largest single genetic target for therapy development. The SOD1 gene, discovered in 1993, became the first genetic target of a clinically approved therapy when tofersen (Qalsody) received FDA accelerated approval in 2023 — though SOD1 mutations affect fewer than 2% of all ALS patients. The extraordinary 1.5–2× elevated risk among veterans remains one of ALS’s most important and least understood epidemiological signals — potentially implicating occupational toxin exposures, traumatic brain injury, or intense physical exertion as environmental triggers in genetically predisposed individuals.

ALS Treatment in the US | FDA-Approved Drugs & Current Standard of Care

Source: ALS Association medications page, Your ALS Guide approved drugs page, Frontiers in Neurology (January 2026 — current/emerging therapeutic strategies), PMC nanotherapeutics review (November 2025), FDA, ALS News Today facts and statistics, JMCP ALS costs study (December 2024), ALS Association FY2024 Impact Report

The ALS treatment landscape in 2024–2026 is defined by the contrast between cautious incremental progress and urgent unmet need. For nearly three decades after its 1995 approval, riluzole stood as the only FDA-approved therapy for ALS — a drug that extends median survival by approximately two months and does not reverse or stop the disease. The 2017 approval of edaravone (Radicava) added a second option with some evidence of slowing functional decline, though subsequent European trials did not replicate the benefit seen in Japan and the US, leaving the clinical community divided on its real-world value. The 2022 approval of AMX0035 (Relyvrio) appeared to mark a genuine therapeutic advance — but its voluntary market withdrawal on April 4, 2024, following the Phase 3 PHOENIX trial’s failure to confirm Phase 2 benefit, was a significant setback and a sobering reminder of how difficult it is to translate early ALS trial results into confirmed clinical benefit.

The most genuinely encouraging development in ALS treatment is tofersen (Qalsody), which received FDA accelerated approval in 2023 as the first precision medicine for ALS — targeting the SOD1 gene specifically. The 38% reduction in SOD1 protein and 67% reduction in neurofilament light chain (a biomarker of neurodegeneration) seen in trials are clinically meaningful markers. The drug’s limitation is its narrow eligibility: only the approximately 2% of ALS patients with SOD1 mutations can benefit. But tofersen is now explicitly a proof of concept — it demonstrates that gene-targeted antisense oligonucleotide (ASO) therapy can affect ALS biology when the correct genetic target is identified. The same approach is now being applied to C9orf72, FUS, TARDBP, and other genetic variants, with multiple Phase 3 trials underway as of 2025. The broader lesson from tofersen is that ALS may need to be treated as a collection of genetically distinct diseases rather than a single clinical entity — a paradigm shift that has major implications for clinical trial design and drug development strategy.

ALS Prevention & Research in the US | What Can Be Done

Source: Cleveland Clinic ALS page, CDC National ALS Registry (cdc.gov/als), ALS Association FY2024 Impact Report, ALS Wikipedia (updated April 2026), BCBSM genetic testing policy (2025), AllMedRx ALS therapies 2025, Target ALS statistics, ALS News Today November 14, 2025, Frontiers in Neurology (January 2026), JMCP/ALS News Today (December 2024)

The honest answer to “can ALS be prevented?” is that no proven prevention strategy exists for the vast majority of cases. Because roughly 90% of ALS is sporadic — occurring in people with no family history and, often, no identifiable genetic mutation or environmental exposure — there is no equivalent of a cancer screening program or a cardiovascular risk-reduction protocol to apply. The genetic counseling and testing guidelines published in September 2023 mark genuine progress for the 10% of patients with familial ALS: for those who test positive for SOD1 or other pathogenic mutations without yet showing symptoms, presymptomatic tofersen trials are now exploring whether starting treatment before clinical onset can delay or modify disease development. That research represents the first real glimpse of a prevention-adjacent strategy for ALS.

For the broader population, the most actionable insights from the research evidence are around reducing diagnostic delay and ensuring access to multidisciplinary ALS clinic care. A 2024 Biogen-funded study published in the Journal of Managed Care & Specialty Pharmacy found that early-stage patients cost payers an average of $31,000 annually versus $120,000+ at late stage — and that delays in diagnosis drive patients to costly, inefficient healthcare utilization pathways before their ALS is recognized. Multidisciplinary ALS clinic care — coordinating neurology, respiratory medicine, nutrition, speech therapy, physical therapy, occupational therapy, and social work — is associated with the best clinical outcomes of any non-pharmacological intervention, but it remains geographically and financially inaccessible to many patients, particularly in rural areas and among under-resourced populations. The CDC’s projection of 36,308+ cases by 2030 combined with the researchers’ own acknowledgment that this is likely an underestimate means that healthcare systems planning for neurological disease burden should treat ALS as a growing — not a stable — challenge that will require meaningfully increased investment in specialists, infrastructure, and pharmacological innovation over the coming decade.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE